One important metric to look for in a stock is an 80 or higher Relative Strength Rating. GSK ADR now clears that threshold, with a jump from 78 to 82 Thursday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the market's biggest winners often have an 80 or better RS Rating as they launch their biggest runs.
GSK ADR is working on a consolidation with a 45.92 buy point. See if it can clear the breakout price in heavy trade.
Earnings grew 6% last quarter, up from -22% in the prior report. Revenue also increased, from -1% to 4%.
GSK ADR earns the No. 3 rank among its peers in the Medical-Diversified industry group. Eli Lilly is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
